If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Forma Therapeutics Holdings, Inc. (FMTX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Their drug discovery expertise has generated a pipeline of small molecule product candidates focused on indications with significant unmet patient need. Their pipeline consists of seven product candidates, two of which they are pursuing as core product candidates for development, FT-4202 for the treatment of sickle cell disease, or SCD, and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. Their lead core product candidate, FT-4202, is a novel, oral, once-daily, potentially disease-modifying therapy initially being studied for the treatment of SCD, one of the most common single-gene disorders in the world. FT-4202 is a potent activator of pyruvate kinase-R, or PKR, designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. They are evaluating FT-4202 in a multi-center, placebo-controlled Phase I trial in SCD patients ages 12 years and older. They completed the healthy volunteer portion of the trial in May 2019 and presented data at the 2019 American Society of Hematology meeting demonstrating the tolerability and proof of mechanism of FT-4202 in healthy volunteers. They reported data from a single dose cohort in seven SCD patients in May 2020.
Frank D. Lee Todd Shegog
Employees Founded
80 2007


Address: 500 Arsenal Street, Suite 100, Watertown, MA 02472, US

Telephone: (617) 679-1970

Web page:

IPO information

Expected Date 6/19/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $625.2
Revenues (MM) $28.5
Net Income (Loss) (MM) $-51.2


What do you think will happen with the FMTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 11.76
Shares Revised (MM) 13.8
Expected offer amount (MM) $199.92
Realized offer amount(MM) $276
Jefferies/ SVB Leerink/ Credit Suisse

Sector: Healthcare

Tweets about $FMTX

Tweets volume:

RT volume:


Google Trends Stats